Johns Hopkins researchers report in Annals of Internal Medicine that the pill drew in new patients rather than pulling them away from injectable Wegovy or Zepbound.
Recap by typeshit. Full story at Newswise.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Neither has a controlled human trial for sports injuries. An FDA advisory panel voted 8 to 6 in July 2026 to back compounding BPC-157, but the FDA has not decided.
17:54
Dr. Stirrett weighs the two drugs against each other for people over 50 trying to lose weight.
Loading…